Good morning, and welcome to the Boston Scientific First Quarter 2026 Earnings Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.

Thank you, Bailey, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer, John Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and John will be joined by our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q1-2026 results, which included reconciliations of the non-GAAP measures used in this release. The release, as well as reconciliations of non-GAAP measures used in today's call, can be found on the Investor Relations section of the website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for which there is less than a full period of comparable net sales. Guidance excludes the previously announced agreement to acquire Penumbra, which is expected to close in 2026, subject to customary closing conditions. For more information, please refer to the Q1 financial and operating highlights deck, which may be found in the investor relations section of our website. On this call, all references to sales and revenue are organic, and relative growth is compared to the same quarter and prior year, unless otherwise specified. This call contains forward-looking statements regarding, among other things, our financial performance, business plans, and product performance and development. These statements are based on our current beliefs, using information available to us as of today's dates, and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect or certain risks or uncertainties materialize, actual results could vary materially from those projected by the forward-looking statement. Factors that may cause such differences are discussed in our periodic reports and other filing for the SEC, including the risk factors section of our most recent annual report on Form 10-K. Boston Scientific disclaims any intention or obligation to update these forward-looking statements, except as required by law. In addition, this call does not constitute an offer to sell or the solicitation of any offer to buy any securities or solicitation of any vote or approval in connection with a proposed transaction with Penumbra. Boston Scientific has filed this SEC, a registration statement on Form S-4, containing a proxy statement of Penumbra and a prospectus of Boston Scientific that contains important information about Penumbra, Boston Scientific, the proposed transactions, and related matters. At this point, I'll turn it over to Mike.

Thanks, Lauren, and thank you to everyone for joining us today. First quarter represented a solid quarter for Boston Scientific with total company organic sales growth of 9.4% versus our guidance range of 8.5% to 10%. First quarter adjusted EPS of 80 cents through 6% achieving a high number guidance range of $0.78 to $0.80, and Q1 adjusted operating margin was $0.28. Turning to our outlook, 2026 has proven to be a more challenging year than we initially expected. To that end, we are guiding into organic growth of 5% to 7% for second quarter and reducing our full year guidance to 6.5% to 8%, reflecting unanticipated headwinds and and changing business patterns that I'll cover in more detail on this call. Our second quarter 26 adjusted EPS guide is 82 to 84 cents, but we now expect our full year adjusted EPS to be 334 to 341, representing growth of nine to 11%. I and our company does not take this change lightly, as I and Boston Scientific take great pride in ourselves and consistently execute it against the guidance and goals we provide. Importantly, we remain convicted in the future Boston Scientific. We have a strong global team committed to high performance and we continue to invest in key new and existing markets which we believe will enable us to deliver in our fundamental goal of driving differentiated performance over the LRP. I'll now provide some additional highlights of our first quarter along with some comments on our outlook. Regionally and on operational basis, the U.S. grew 11% with double-digit growth in five out of our eight business units. Europe, Middle East, Africa grew 1% operationally. Growth in the quarter was driven by ferrapulse, coronary, and vascular therapies in Neuromod, offset by the discontinuation of Acura and PolarX, largely impacting the Amir region. Last year, we did announce our intent to discontinue the PolarX cryocatheter, but have accelerated that timing given some recent safety events and the availability of non-thermal ablation technologies. As we look forward, we expect that growth in demand will continue to improve with the annualization of the accurate discontinuation in 2Q and ongoing momentum from Farapulse, Watchman, and other key products. AsiaPAC delivered a strong quarter and grew 12% operationally, led by double-digit growth in a number of countries, including Japan and China. First quarter growth in Japan was led by our differentiated PFA ecosystem with Opal, Fairview, and Farapulse, as well as strong reception of Watchman FlexPro. Within the quarter, we're pleased to have received PMDA approval for the de novo indication of our coronary dry-coded blue agent DCB, expanding the patient population eligible for this differentiated technology. China also delivered strong growth, inclusive of the impact from the BVP, led by our interventional cardiology portfolio, particularly our imaging technologies. We are making consistent progress against our fearful skulls in a competitive market in China and received NMPA approval within the quarter for Opal HDX mapping system with Fairview, further building out the PFA platform. Now some commentary on our business units. I'll start with Urology. Urology did have a difficult quarter in Q1 as sales grew 1% organically, falling short of our expectations driven primarily by the Stone management and sacral neuromodulation businesses. Within Stone, underperformance is driven by China VBP, as well as some key product gaps in the core Stone portfolio. We expect the recent FDA approval for insurers to unlock value within our StoneSmart ecosystem, alongside LithuView Elite. And we also anticipate launching additional new products in 2026, including a slim urethroscope later this year. Our cyclone neuromodulation business continues to see impact on commercial model disruption. And importantly, within first quarter, we have hired and trained a significant number of new sales and clinical reps, and we do anticipate improvement in this pelvic health franchise throughout the year as the S&M commercial organization capabilities stabilize, along with the addition of e-coin to the nerve stem with the closure of Valencia Technologies in April. We expect our urology performance to improve throughout the year. However, we now expect our full-year euro growth to be low to mid-single digits in 2026. Admoscopy sales grew 7% organically, with strong results across the business and better than anticipated performance from Axios, as we're able to ramp supply and available product As we look to the second quarter, we will continue to see some impact from Axios while also navigating other transient supply chain disruptions in admoscopy. Importantly, we expect improvement in the second half of 2026, as the underlying business is very strong and we anticipate resolution of the supply chain issues. Neuromodulation has a strong quarter, with agranic sales growing 15%, with our comprehensive portfolio growing low double digits, excluding the impact from NALA. Our pain business grew mid-teens, inclusive of the strong quarter from NALA, as I mentioned, which closed at the end of January. Intracept continues to perform well, supported by compelling FIGER data demonstrating the long-term efficacy and cost effectiveness of this treatment for chronic low back pain. In DBS, we saw continued adoption of the Cartesia X leads and accelerating uptake of the Illumina 3D programming algorithm in the U.S. Cardiovascular-delivered organic sales growth of 11%. Within those businesses, we'll start with ICDT. Interventional cardiology vascular therapies grew organic sales 8%. This business grew 9% organically, driven by double-digit growth in our coronary therapies franchise, with strength and agent and ongoing momentum with our imaging portfolio. And earlier this year, we completed an enrollment in our fracture trial, studying the seismic IVL device in coronary arteries with data to be presented at EuroPCR on May 19th. We continue to expect launch in the U.S. in the first half of 27. Our vascular therapies business had a nice quarter, growing 7% organically, driven by double-digit growth in TCAR and Verathena. And this is offset by large VBP impact on the arterial business in China, which is expected to annualize in second quarter. We expanded our launch with our seismic peripheral IVL for above the knee with positive physician feedback on performance. We expect to ramp our manufacturing supply chain over the course of the year and continue to anticipate launching our below the knee indication in the second half. In the first quarter, positive data from HyPytho was presented at EACC evaluating ECOS plus anticoagulation versus anticoagulation alone, providing new clinical evidence that can help physicians make more informed treatment decisions for patients with acute pulmonary embolism. We remain excited about the opportunity to add the Penumber team and a highly differentiated portfolio to Boston Scientific. We anticipate that the deal will close on the 2nd after 26th, subject to the Penumber shareholder vote on May 6th, and the receipt of the remaining regulatory clearances. Our interventional oncology business had a nice quarter with organic sales growing 15%, driven by our broad offering of cancer therapy technologies. Within the quarter, we received FDA clearance of any day dosing and initiated a limited market release. Any day dosing is enabled by the TheraSphere 360 Y90 management platform, allowing physicians to schedule treatments on more days of the week and offering more streamlined ordering and operational efficiency. Sales declined 3% in the quarter. Our low-voltage business saw some impact in the quarter as we navigated our physician advisory and came up against a tough comp within our first quarter 2025 change-outs. On the high-voltage side, we saw some impact from the Middle East conflict impacting this particular business. In the first quarter, our diagnostic franchise grew low double digits with continued strength across our broad diagnostic portfolio. And overall, we anticipate that our CRM business will return to growth in the second quarter and expect a low single-digit growth of the year, supported by our full launch of the loop row in the second quarter within the U.S. Watchmen grew 19% organically in the first quarter, which was below our expectations, with pressure on volumes in the U.S. as the quarter progressed. We believe this reflects the annualization of the initial concomitant adoption tailwind and a softening in stand-alone Watchmen cases driven by hospital capacity, related procedure prioritization, and evolving reimbursement dynamics. Importantly, we remain focused on expanding physician and patient education within the approximately 5 million patient-indicated population today, and we expect data from Champion to support a return to 20% market growth over the LRP. In late March, Champion data was presented as a late-breaker at ECC with the trial achieving all primary and secondary endpoints, reinforcing the safety and efficacy of watchmen, and highlighting the high burden of clinically relevant bleeding on oral antidepressants. The next step, in addition to submitting for a label update, we are working with medical societies to support consideration of changes to LAAT guidelines using the totality of Watchman clinical evidence ahead of any update to the national coverage of the term. We presented HRS this weekend, a champion post-ablation analysis, which will provide further insights on this patient population. Across the globe, the resulting chanting provide important evidence to support the expansion of the patient population eligible for watchmen over time at large markets including the US, Japan, China, and Europe. For full year 26, we now expect global watchmen growth to be mid-teens with low to mid-teens in the US. In the US, while concomitant demand continues to strengthen, we anticipate overall watchmen growth to decelerate with tougher comps and expect stand-alone Washington procedures to improve over the course of the year as it takes time for the totality of this clinical evidence to translate into clinical practice. We remain very confident in the long-term outlook of the business supported by great clinical evidence, market development, and new product innovation. Turning to EP, organic sales grew 22%, 18% in the U.S., and 30% internationally. International growth was driven by our innovative portfolio, including our expanded opal mapping footprint and catheter utilization, with strong double-digit PFA growth in Europe, in a highly competitive environment supported by the launch of Fairpoint. U.S. growth is driven by continued expansion of the opal, strong catheter utilization, and Fairpoint, our PFA focal point catheter, which is performing ahead of our expectations and has moved into full launch. Looking ahead, we now expect a global EP business to grow approximately 10% in 2026. And within the U.S., we are updating our full-year expected growth to be in the mid-single-digit range with continued strength internationally at plus 20%, inclusive of a full-year impact of approximately $35 million from the discontinuation of PolarX. This outlook is a change from previous commentary, but we feel it's prudent and reflects ongoing competitive dynamics offset by strength in our evolving Fairer Pulse PFA catheter and mapping portfolio. We are highly confident in our ability to maintain our leadership position in PFA both in the U.S. and internationally through investment and commercial capabilities, ongoing clinical evidence, our expanding mapping footprint, and an impressive next-generation catheter launch is including our Fairwave Ultra in the first half of 27. And this weekend, avant-garde has studied Ferrafalse, a new patient population of drug naive persistent AF patients will be presented as a late breaker at HRS. Additionally, we will see data from our first in human Elevate PS study studying Ferraflex, which is our large focal map in a blade catheter for more complex arrhythmias. We anticipate initiating in our IDE later this year and continue to expect launching Ferraflex in the U.S. in 2028. So in closing, I'd like to share again my confidence in our team and the future of Boston Scientific. While this year has proven to be more challenging than we anticipated, we believe Boston Scientific is competing in the right markets with a waiver of approximately 8% and we continue to be uniquely positioned to drive differentiated top-line growth. We will continue to do this through strategic internal innovation, clinical evidence, external VC and M&A investments along with a disciplined approach to expanding operating margins, all of which have resulted in our track record of delivering double-digit adjusted EPS growth. I'm very grateful to our talented team of global employees who work every day to advance science for life and have confidence in the sustainability of our top-tier financial performance. With that, I'll hand it over to John.

Thanks, Mike. First quarter consolidated revenue of $5,203,000,000 represents 11.6% reported growth versus first quarter 2025 and includes a 220 basis point tailwind from foreign exchange which was in line with our expectations. Excluding this $104 million foreign exchange tailwind, operational revenue growth was 9.4% in the quarter. Organic revenue growth was also 9.4% in line with our first quarter guidance range of 8.5% to 10%. 2021-2026 adjusted earnings per share of 80 cents grew 6% versus 2025 achieving the high end of our guidance range of 78 to 80 cents. Results include an approximate one cent headwind from FX. Adjusted gross margin for the first quarter was 70.5 percent which represents a 100 basis point decline versus the first quarter of 2025 primarily driven by tariffs as well as inventory charges related to the discontinuation of our Polarex cryoablation system. We now expect full year 2026 adjusted gross margin to be slightly below full year 2025, largely given by lower than expected product mix benefit and incremental investments in our global supply chain and quality systems. First quarter adjusted operating margin was 28.0%. We continue to expect full year 2026 adjusted operating margin expansion of 50 to 75 basis points, driven by OpEx leverage as we drive strong spend controls and continue to implement efficiency initiatives and optimize our organizational structure. On a gap basis, first quarter operating margin was 21.2%. Moving to below the line, first quarter adjusted interest and other expenses totaled $112 million in line with expectations and our adjusted The tax rate for the first quarter was 11.7%, which was in line with expectations and includes a benefit from stock compensation accounting. Fully diluted, weighted average shares outstanding ended at 1,495,000,000 shares in the first Free cash flow for the first quarter was $170,000,000 with $348,000,000 from operating activities less $177,000,000 in net capital expenditures. We now expect full-year 2026 free cash flow to be approximately $4 billion. As of March 31, 2026, we had cash on hand of $1,453,000,000, and our gross debt leverage ratio was 1.8 times. Our top capital allocation priority remained strategic tuck-in M&A, followed by share repurchase. In alignment with this strategy, we recently closed the acquisition of Valencia Technologies, which complements our urology business and we expect our announced acquisition of Penumbra to close in the second half of 2026. In addition, as previously disclosed, our board of directors recently approved an additional four billion dollars under our existing share repurchase program bringing our total authorization to five billion dollars. While we have been restricted from being in the market, we intend to repurchase approximately two billion dollars of our shares during the second quarter, subject to market conditions and applicable securities laws. I'll now walk through guidance for Q2 in full year 2026. We now expect full year 2026 reported revenue growth to be in a range of 7.0% to 8.5% versus 2025, excluding an approximate 50 basis point tailwind from foreign exchange based on current rates. We expect full year 2026 operational and organic growth to be in a range of 6.5% to 8.0%. We expect second quarter, 2026, reported revenue growth to be in a range of 5.5% to 7.5% versus second quarter, 2025, excluding an approximate 50 basis point tailwind from foreign exchange based on current rates. We expect second quarter, 2026, operational and organic growth to be in a range of 5.0% to 7.0%. We continue to expect full year 2026 adjustable line expense to be approximately $440 million. And under current legislation, including enacted laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximately 12.0%. We now expect full year 2026 adjusted earnings per share to be in a range of $3.34 to $3.41, cents, representing growth of 9% to 11% versus 2025, including an approximate $0.04 headwind from foreign exchange. We expect second quarter adjusted earnings per share to be in a range of $0.82 to $0.84. In closing, we recognize that revising our guidance is a significant decision and not one that we made lightly. We believe our updated guidance appropriately reflects the unanticipated headwinds, and we remain highly focused on executing our full year 2026 guidance of 6.5% to 8% organic revenue growth, 50 to 75 basis points of adjusted operating margin expansion and 9% to 11% adjusted earnings per share growth. For more information, please check our investor relations website for Q1 20.6 financial and operational highlights, which outlines more details on first quarter results in 2026 guidance. And with that, I'll turn it back to Lauren, who will moderate Q&A.

Thanks, John. Bailey, let's open it up for questions for the next 35 minutes or so. In order for us to take as many questions as possible, please limit yourself to one question. Bailey,

please go ahead. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2. Again, please limit yourself to only one question. At this time we will pause momentarily to assemble our roster. Our first question comes from Robbie Marcus with JPMorgan. Please go ahead. Oh great, good morning and thanks for taking the

question. I wanted to ask whether Mike or John came two, three months ago, got on the fourth quarter call and provided the guidance. And I think a lot of people were expecting a lowering today based on some of the third-party data we've seen. So it's not that surprising. But I guess the question is really, what happened during first quarter that really prompted it? When did you realize it? And what gives you the confidence, given there's going to be some deceleration throughout the year, that the LRP is still valid and that growth can improve in 2027 here?

Thanks a lot. Yeah, thanks, Robbie. Good morning. I would say, you know, first quarter, we're overall we're pleased with that result you know the 9.4% growth an on track for our margin in EPS you know essentially what we saw there's really three main contributors to the take down the guide which is not my happiest moment and very disappointed in that as we as we're a company that consistently delivers on our commitments so this is a guide down that we quite think are not proud of but that we think it's the right thing to do and best reflects the current environment and the loss of the proper prudent guide to do. We can talk about the future of the company, but speak in a minute, but talk about the takedown. Particularly, it's really focused on the three areas, primarily EP, Watchmen, and Urology. And if you start with Watchmen, we saw very, very excellent growth, as you know, in 2025. We grew almost 30%. we saw really strong, consistent volume trends in January. So there was no signal to any watchman weakness until we really saw the early days of kind of early to mid-February. We started to see declining watchman volume. And as we did the analysis on that, we can talk more about it. Essentially, it is a strong increase in concomitant growth and a deceleration of standalone watchmen. And I'm going to go through all those details now. That's the first primary one. So we see a declining Watchman trend growth throughout the first quarter. And therefore, in our guide, we think it's prudent to assume that in that guidance range. We can talk more about the rationale and reasons for that. The second primary reason is EP. Our EP business had a very nice first quarter. We are absolutely confident that we will remain the PFA market leaders in the U.S. and globally in 26. and we have a very rich cadence. I just did an R&D review last week with the team. If it launches the next two and a half years, that's very impressive. But that being the case, even though the market's strong, we did lose a bit more share than we anticipated. So again, what we did in this guide anticipated greater share erosion than we're particularly seeing where we're guiding globally to approximately 10% NEP. And the last reason making up is urology, which I mentioned that difficult quarter, first quarter, you know, Neuromod had a real tough year a couple years ago, and that business is growing double digit. I'm not saying Euro is going to return a double digit right away, but right now we're suffering in our core stone business and in the sacral nerve modulation area. We have very active execution plans in place to fix sacral nerve modulation, which we believe will be better as the quarters go on. And in the core stone, we have some key product launches that will impact that business and help quite a bit in 2027. But That's essentially going to be a below market year in urology. So those are the three contributors overall to the guide down. Now, we're all done very objectively. We think it's prudent, and we think it's the best guide to provide to give shareholders confidence and to set up the business the right way. As you look forward in the LRP, we're not going to make a comment on the LRP top line growth at this point. We feel that will be under some slight pressure, clearly given the 2026 guide. We will update that more in the future when we go through our strat plan process. We are comfortable with the 150 basis points of margin improvement in LRP, and we're comfortable with delivering WGPS growth through the LRP. And I guess lastly, the long answer I'm giving you is we compete in a 8% WAMGAR market. We almost always grow at or above this WAMGAR. And this setup for 26 would show us at market at the high end of our guide or below that land room. This is not Boston Scientific. It's not what we do. And in 27, we have a number of key product launches. We'll have far easier comps than we do this year. And we're very bullish about 27 and 28. We can detail that more. But sorry for the long response. Hopefully that helped a little bit.

Our next question will come from Joanne Winch with Citi. Please go ahead.

Thank you for taking the question. And, Mike, I think you just summarized what everybody needed to hear in that answer. Can you sort of walk us through a little bit how you're thinking about the quarters over the next couple of quarters, particularly for EP, Watchmen, and Euro? I'm sort of trying to think about the gist of Robbie's question. How do we get from first quarter to fourth quarter and then the jumping off point into 2027? and I just want to make sure those are somewhat set up appropriately. Thank you.

I'll take a shot, and John, you can clean up if I'm a mess here. So we think second quarter is our toughest quarter. We have a nice first quarter. Second quarter, we have very challenging dollar sequential quarterly growth comps on a dollar basis, in particular, with EPA and Watchmen. So that's our toughest quarter there. and so we also think with some of the impacts of some transient trends in endo and some other areas that will be fixed for the second half of the year. So we think second quarter is our toughest quarter. That's the guide five to seven and the full year guide, as you know, is six and a half to eight percent.

John, do you want to touch on any sequencing more? Yeah, thanks, Joanne. So maybe stepping through Watchman and EP. So you heard Mike mention in his prepared remarks, we expect global EP to grow mid-teens for the year. So that would imply, Joanne, low double-digit growth for the rest of the year for our global Watchman business. So that's how you should think of Watchman for the rest of the year. Global EP at 10% for the year implies mid to high single-digit growth for the rest of the year. So if you then think of the rest of the business as mid single-digit growth, that's about where we landed in the first quarter, expect to see some acceleration there within urology, CRM to pick up. So that's how you should expect the phasing as we go through the year. I'd say relatively consistent, slight uptick in the second half. They call it roughly 7% as we see euro and CRM drive better growth as we move through the year.

Our next question comes from Larry Beigelson with Wells Fargo. Please go ahead.

Good morning. Thanks for taking the question. I guess on EP, just maybe a little bit more color on the market and share assumptions, how they've changed. Where is this share pressure coming from, Mike? And on USEP, sales have been flattish for the past three or four quarters. Should we expect relatively flat USEP sales for the rest of the year? And what does that mean for 2027? I think people are trying to understand when you can get back to market growth in EP.

Yeah, I think John's gave some of those numbers. For EP, for the year, we expect global to be approximately 10%. In the U.S. particularly, we expect mid-single-digit growth for the U.S. business, which implies a flat 2Q to 4Q. Flat is a low single-digit. In international, about 20%. So I call it flat or low single-digit U.S. mid-single-digit for the year. And then so that's the story there. what's different about it from our previous commentaries where we've said we were a grow hat market we're disappointed and we're disappointed to bring that that guy's level down but we think it's appropriate we aim to be and we have high confidence that will maintain PFA leadership in the US internationally globally in 26 and throughout this LRP and we are very excited about the product launch that we have in particular for the three big ones coming up. 27 are third-generation Farapulse, a differentiated ice platform, and we think a very disruptive Faraflex platform all in the next two and a half years. But today we are seeing increased competition. You know there's three other large players in the marketplace. We've made commentary before. Medtronic continues to be a solid competitor. J&J is enhancing their footprint in PFA. and Abbott at his early stages of launch in the U.S. In Europe, we're really proud of our European performance where all three of those companies are performing, and we continue to grow at a 20% plus clip where we quite frankly have a quite advanced mapping capability and platform and doing very well there. So we did expect a little bit more share erosion than we've anticipated in the past and previous guides, but we think this is the perfect guide to do and allows us to continue that PFA market leadership why we're bringing that platform forward and importantly our mappers which we've made a massive investment over the past two and a half years continue to get stronger and stronger every quarter we continue to install more and more opal mapping platforms our mappers get more sophisticated and we continue to add new catheters to the mix along with ferroform which we recently launched so we'll continue to grow the mapping platform continue to invest in that commercial capabilities. You'll see more direct investments in Watchmen in particular, so we'll invest both commercially and marketing in both our Watchmen and our EP businesses. But we're confident we'll maintain PFA leadership, but we are going to see a bit more share than we anticipated

earlier in the year. Our next question comes from Rick Wise with Stiefel. Please go ahead.

Good morning, and thanks for taking the question. I was hoping you might talk a little bit more about the Watchmen outlook in more detail. I mean, Champion data obviously was excellent, but perhaps there was more controversy about the data and the reaction to the data than I expected and perhaps than you expected. How are you addressing some of the concerns that you were left with? How are you changing the narrative about the risks of Watchmen And then maybe how specifically are you going to tackle the growth rate factors that impacted this quarter? Thank you very much.

Yeah, I'll ask Ken to add commentary here. You know, first on some of the factors, and first of all, we're very proud that we essentially created this category, leaving in clinical science, created the concomitant category. And this category grew 30% last year, and we expected mid-teens growth this year. And we're seeing evolving practice patterns as this product continues to evolve with great clinical data and changing practice patterns. So with that extraordinary growth in AF tibulations and Watchman, we are seeing some practice pattern changes that I highlighted that we saw really become more acute in February. we're seeing terrific concomitant demand, bottom line. We are seeing pressure in kind of the stand-alone watchman implant business, which historically has not been a challenge for us. Those challenges with a stand-alone watchman area are a bit multifactorial. We're seeing a bit more switch to the EP from the interventional cardiologist. The interventional cardiologist is less exposed to the concomitant procedure. They've got more structural art procedures to do, and there's a bit of the reimbursement cut in that area. But you're seeing strengthening amongst the EP physician group. So those are some of the trends that have really moved it just recently, a bit more towards EP, a bit more towards concomitant, and less than standalone. And our customers are also adapting to operational workflow. They're adding new labs, they're moving to ASEs because they've experienced multi-year growth of, call it 25% in Watchmen, multi-year growth of 20-25% in ablations. So there's a significant demand and pull plus the approval of new structural heart procedures. So the hospitals themselves are investing in labs. Particularly concomitant, AFib are money winners for hospitals. So they're making the investments, but they're also moving through their own workflow challenges. We've seen a consistent backlog for Watchmen, which I guess is good, and high demand obviously for Aten. So on what are we doing to make it better, we're doing a lot right now to make it better.

The most impactful thing quickly is commercial investments.

We are putting more focused commercial investments directly at the Watchmen business. Today we have a lot of strength because the same territory rep in many cases is serving both the EP customer, EP, and watchmen. We're going to augment them with additional focus on watchmen specifically and put a little more emphasis and focus directly at that interventional cardiology call point. We'll be making quite a bit of marketing investments to really highlight the outstanding data that we believe, the first study of its time that met its primary endpoints and champion that Ken can detail. So commercial investments, Medicare investments, marketing investments, position activation investments, all the leverage champion. It's also important to note that Ken can talk, sorry, too much coffee. Today, 25% of all watchbook procedures are in common. We do expect that to grow to 50% over the LRP, so that view hasn't changed. What we've seen is an offset a bit in stand-alone watchman procedures. Anyone want to talk more about that?

I don't have too much to add, but again, I think the first thing I'd say in terms of question, it just takes time to disseminate data and to educate physicians on the results of things like Champion. And of course, we were not able to get out and pre-promote ahead of the data release and ahead of the publication in the New England Journal of Medicine. Having said that, the trial kit, all of its primary safety and efficacy endpoints and all of the important secondary endpoints, we do still anticipate that we will get a fake labeling, a fake to guidelines, and eventually an updated national coverage determination. It just takes time for that to play through. And then I think the other thing, just to reiterate what Mike said, you know, in parallel with that, we see the opportunity to continue to improve some of the operational efficiencies that are required, just to unlock more operational capacity for handling these procedures. We see hospitals building out more labs dedicated to these procedures. The move of simple ablations to AFCs will further unlock capacity. And again, just to highlight what Mike said, we see a very large opportunity for continued growth in concomitant procedures. And maybe the one statistic I'd add to what Mike said just to remind everyone. You know, roughly 50% of the patients for AFib in the U.S. today are done in patients who are at high risk of stroke, who have a CHSVAT score of three or higher, and who are potentially candidates for a common procedure.

Our next question comes from David Roman with Goldman Sachs. Please go ahead.

Thank you. Good morning, everybody. I wanted maybe just to toggle over to the other 70 plus percent of the business that's non-EP and Watchmen and appreciate some of the dynamics that you walked through on the call. But maybe you could unpack a little bit for us in more detail, kind of where you see that cohort of the business going, some of the specific product launches that you expect to see in 26 and 27 that we should be watching, and the extent to which that piece of the business can get back toward kind of an 8% growth level where it was called before the accurate discontinuation.

Sure. Thank you for the question, Dave. The area that's not getting the spotlight on it is this ICVT, Intervention Cardiology and Vascular Therapies Group, which, again, has that one-timer of an accurate, which will anniversary, thankfully, in May, which will help that business. But that business is at a very high level, driving a double-digit growth in China despite EVP, a very global business. Agents is continuing, and our imaging businesses in particular, continue to exceed our internal expectations, which is terrific. And we're excited about the seismic launch that's really been in the small scale thus far within our purple vascular business. It's been very well received by physicians. And that fracture trial will read out at PCR in a month or so. And we expect to have that coronary approval as we enter 2027. And we're focused right now on building up the manufacturing supply chain to enable a meaningful launch for seismic for both coronary and below-the-knee and above-the-knee applications in 2027. So they also have a number of kind of singles then doubles key product launches in vascular. continue to widen that portfolio out. The interventional oncology business grew mid-teens and I talked about a key workflow launch that they additionally had along with some second M&A that they're executing on and hopefully the shareholder vote goes positive for us with the number on May 7. We're really excited about that team which is extremely talented and brings a really differentiated portfolio in gaps that we have across Boston Scientific in that category. So particularly in combination, you know, stand alone without Penumbra, that business is extremely well. In the future, ideally with Penumbra, that's a very unique, powerful growth driver for the company over this LRP period. And I think a lot of the discussion will still be on watchman EP, but much more will pivot to that area given the watches and momentum in that area. Lastly, I would just try to summarize mid-surg. Overall, similar to EP, you know, we've had some challenges right now in urology. We're not happy with a 1% growth in the quarter. We have clear line of sight to how we're going to adjust and fix that. as that business will improve in 2026 but not the level that we expect our business to perform at and we'd be highly disappointed if we were closer to market growth to that business in 2027 endoscopy is doing well they've got a nice set of product launches coming over the next nine months and our neuromod business is growing double-digit so overall med surge is a tick lighter in 26 that we anticipate and we say that business will improve as the kind of quarters move on in 26 and will have a stronger 27.

Our next question comes from Travis Steed with Bank of America. Please go ahead.

Hey, everybody. On the WAMGR, I think there was a slight change to the WAMGR from 9 to 8. I wanted to touch on that. And on the LRP, was the message more we're not achieving a 10% or was it more we'll kind of wait and see how it all plays out? because I'm thinking about 27. You sound pretty bullish on 27. No headwinds. You have product launches. So just kind of curious about LRP.

On the Wanger's average, I think we were pretty clear at the investor day that we were at 8% moving to 9% over the LRP. So I believe that was the message on the Wanger. So we call it 8% moving towards 9% because we're in the right high-growth markets. So I think that's consistent. LRP. LRP. Oh, and LRP, I mentioned in the previous commentary. So what we are confident in giving you now is we're confident in our ability to continue to have the discipline to improve margins at that 150 basis points. We're confident in our ability to execute double-digit EPS over this LRP period. And on the sales side, obviously with a guide at six and a half to eight, that puts pressure on the 10% plus guide we gave at LRP. So, you know, I would say that's likely an upside scenario at this point, but it's premature for us to give you a LRP, organic revenue growth number at this point, and let us work through our strategic plan and launch cadence, and we'll update that over the course of

Great.

Our next question comes from Josh Jennings with T.D. Please go ahead.

Thanks for taking the questions. I just wanted to touch on the EPS guidance revision. I think some may be concerned that with deceleration and high-margin products, USCP franchise and Watchman franchise, that there may be incremental pressure there. But any more details you can share just on any offsets or the impact on profitability with the revised outlook for USCP and Watchman? Thanks for taking the question.

Yeah, thanks, Josh. so we'll see less mixed benefit than what we expect at the start of the year so that's why we expect our gross margins now will be slightly lower than 2025 but what we're doing is really driving leverage across OPEX so most immediately we put in much more restricted spend controls across the company. So what we're doing is we're reducing spend that isn't correlated to revenue generation or that isn't pointed at our key product pipeline programs that we have in place. You know we've also had more broadly a number of org structure optimization initiatives in place that includes scaling our centralized shared services. We've got a number of AI automation other initiatives already in place Josh that drive cost efficiency and productivity and so we're looking at those for what we can accelerate and then as it relates to the R&D portfolio we're looking across each of the businesses they are ensuring that we're appropriately fueling and appropriately focusing on the most impactful programs but then those that are less impactful we're looking at how we can trim those so we've got a number of initiatives Josh Josh focused on how do we drive our OpEx toward the most impactful areas of the business and toward revenue generation, and then everything else we're squeezing.

Our next question comes from Marie Thiebaud with BTIG. Please go ahead.

Good morning. Thanks for taking the question. I wanted to double back to urology. I think you mentioned you have some active execution plans in place for improving the sacral neuromodulation business. Can you just dive a little deeper into that? I know that that's something you've been focused on for a couple quarters. Maybe it's going a little bit slower than hope. So if you can just give us an update on how that is going.

Yeah, it's definitely gone slower than we anticipated. We had too much commercial turnover is the bottom line over the course, taken over the course of the last six to nine months. And we certainly learned from that. We made adjustments to it. But at this point in time, we feel we have the right leadership structure in place, you know, from region managers on up that are so key to driving a business like this. We have quite a bit of turnover at the manager level, clinical rep level, and territory level. And so a lot of learning from that as we look forward to Penumbra. But I would say on the management side, that's all been filled up on the region managers, which is important. And we've had, you know, nearly 100 people that have been hired in our various stages of training, both clinical reps and territory reps, to really strengthen that commercial team, which is really needed not only for case coverage, but also to drive the appropriate patient activation events and pull through to appropriate procedures, which is really part of the business and what an area that Axonix did really well. So we're also leveraging a lot of the internal capabilities from Watchmen and others. But it's primarily been a commercial disruption issue that has lingered farther than we wanted it to. But at this point in time, we have made the appropriate hires, the appropriate training, the appropriate investment, and we are confident that we'll see an improvement in that business as the quarters progress.

Our next question comes from Vijay Kumar with Evercore. Please go ahead.

Hi, Mike. Thank you for taking my question. I just – I had one question on this buyback. Generally, when we see companies announce large deals like Penumbra, a $15 billion deal, we generally see buybacks being suspended. So my question is, is the $2 billion buyback in Turkey – is that signaling anything on a deal? And, you know, John, I think you mentioned you have $1.5 billion of cash on hand. How are you affording this $2 billion buyback? Are you going to raise any debt? Why now? Thank you.

Thanks, Vijay. So we intend to, the two billion, we've got one and a half on the balance sheet now and we project our cash over the second quarter. We'll fund that through cash on hand. We've been restricted from trading. We will be restricted at least through the Penumbra shareholder vote on May 6. But as soon as we're not restricted, we intend to repurchase $2 billion worth of shares, as I had mentioned. And why now is we look at the stock price, we look forward at the outlook for the company that we have, our confidence in the company, the pipeline. We think that's a great use of our capital.

Our next question comes from Matthew O'Brien with Piper Sandler. Please go ahead.

Good morning. Thanks for taking that question. I was hoping to talk a little bit about Penumbra. I know the vote's coming up here in just a few weeks. Just curious about Boston's, you know, comfort level in, you know, adding additional cash to that transaction if required, just given the pullback in your stock and the degradation in the value of the overall transaction. If that were to be the case, would you still be committed to the deal at the current or at the previous valuation if a higher cash component is required.

Yeah, I would just comment on Penumbra in general. We've gotten to know their leadership. The momentum of the ICBT team we have and the potential addition to Penumbra we think is a very, very powerful business in combination over time. We've said many, many times that we essentially plan to run Penumbra as a business unit consistent in how we do Boston Scientific. Global presidents keeping their strong commercial team intact, keeping their R&D pipeline. So we have a very solid way to maintain and enhance the penumbra momentum post-closing. We had the shareholder vote on May 7th. We're hopeful and confident that that will be approved as planned.

Our last question will come from Matt Taylor with Jeffries. Please go ahead.

Thank you for taking the question. I just wanted to follow up on some of the comments that you made about the outlook for Watchmen and PFA. Was someone for more clarity on Watchmen in terms of how Standalone was growing? You mentioned it was decelerating. Was it actually declining in Q1, and what's the outlook for Standalone this year and next?

Yeah, we're not going to call it a specific number for Outlook on concomitant specific and Watch Standalone and all that. I think we gave pretty good guide as to what we see as appropriate guidance for the full year on Watchmen, which is global mid-teens, U.S. low to mid-single digits, international. I'm sorry.

Low to mid-teens.

Low to mid-teens, sorry. My bad. I was going to think of EP. Low to mid-teens for U.S. Watchmen and international plus 20, mid-teens growth globally. So that's our outlook, which is obviously a slower outlook than when we saw it in first quarter, but it reflects what I mentioned earlier on overcoming some very, very strong comps, overcoming some efficiency issues that we see that I highlighted before, and more of a trend towards stronger and stronger and prominent and a less strong weakening trend in standalone. them. Now, over time, we aim to try to improve that based on the champion results, the investments we're making. But as I mentioned, you have concomitance, strengthening, standalone currently

less strong. Thank you for joining us today. We appreciate your interest in Boston Scientific. If we were unable to get to your question or you have any follow-up, please don't hesitate to reach out to the investor relations team. Before you disconnect, Bailey will give you all the pertinent details for the replay. Thank you, everyone.

Please note, a recording will be available in one hour by dialing either 1-877-344-7529 or 1-412-317-0088 using the replay code 4539327 until April 29th, 2026 at 11.59 p.m. Eastern Time. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.